鼻型NK/T细胞淋巴瘤发生重度骨髓抑制的危险因素分析  

Analysis on risk factors of severe myelosuppression after the treatment of NK/T cell lymphoma, nasal type

作　　者：李苗苗 张明智[1] Li Miaomiao;Zhang Mingzhi(Department of Oncology, the First Affiliated Hospital of Zhengzhou Unirersity, Zhengzhou 450052 , China)

机构地区：[1]郑州大学第一附属医院肿瘤科,450052

出　　处：《中国实用医刊》2019年第7期37-39,共3页Chinese Journal of Practical Medicine

摘　　要：目的探讨鼻型NK/T细胞淋巴瘤治疗后发生重度骨髓抑制的危险因素。方法选取2010年6月至2016年9月郑州大学第一附属医院诊治的鼻型NK/T细胞淋巴瘤患者108例,根据治疗反应分为重度骨髓抑制组(56例)和非重度骨髓抑制组(52例)。采用单因素和多因素Logistic回归分析重度骨髓抑制危险因素。结果体表面积(OR=0.167,95% CI:0.045~0.614,P=0.007)、诊断分期(OR=1.569,95% CI:1.071~2.298,P=0.021)、治疗方案(OR=1.315,95% CI:1.096~1.578,P=0.003)为发生重度骨髓抑制的危险因素;其中DDGP方案的重度骨髓抑制发生率(52.4%)低于改良SMILE方案(75.0%),差异有统计学意义(P<0.05)。结论体表面积、诊断分期、治疗方案为鼻型NK/T细胞淋巴瘤治疗后发生重度骨髓抑制的危险因素;临床应用改良SMILE方案需警惕重度骨髓抑制,DDGP方案值得在临床推广应用。Objective To investigate the risk factors of occurring severe myelosuppression after the treatment of NK/T cell lymphoma, nasal type. Methods A total of 108 patients with NK/T cell lymphoma, nasal type treated in the First Affiliated Hospital of Zhengzhou University from June 2010 to September 2016 were selected. And they were divided into severe bone marrow suppression group (56 cases) and non-severe bone marrow suppression group (52 cases), according to treatment methods. Univariate and multivariate Logistic regression were used to analyze the risk factors of severe bone marrow suppression. Results Body surface area (OR=0.167, 95% CI: 0.045-0.614, P=0.007), diagnostic staging (OR=1.569, 95% CI: 1.071-2.298, P=0.021), treatment regimen (OR=1.315, 95% CI: 1.096-1.578, P=0.003) were risk factors of severe bone marrow suppression. The incidence of severe bone marrow suppression (52.4%) of DDGP was lower than that of the improved SMILE regimen (75.0%), with significant differences (P<0.05). Conclusions The risk factors of severe myelosuppression after the treatment of NK/T cell lymphoma, nasal type were surface area, diagnosis stage and treatment regimen. Severe bone marrow suppression should be alert in clinical application of the improved SMILE protocol, and the DDGP protocol is worthy of promotion.

关 键 词：NK/T淋巴瘤 骨髓抑制 多因素LOGISTIC分析 

分 类 号：R733.1[医药卫生—肿瘤]